News from immune pharmaceuticals inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( OTC-PINK:EPCTD,OTC-QX:IMNP,OTC-QX:EPCTD,Stockholm:IMNP)

Feb 10, 2016, 09:40 ET

Immune Pharmaceuticals Files New Patent Application for Ceplene in Combination with Checkpoint Inhibitors

Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company, announced today that it has filed a patent...

Feb 08, 2016, 07:30 ET

Immune Pharmaceuticals to Present at 18th Annual BIO CEO & Investors Conference

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company announced today that Dr. Daniel Teper,...

Feb 03, 2016, 07:30 ET

Immune Pharmaceuticals Names John Neczesny to its Board of Directors

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company, announced today that it has...

Jan 12, 2016, 08:00 ET

Immune Pharmaceuticals Announces 2016 Immuno-Oncology Plan

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company, announced today that it has prioritized its...

Jan 04, 2016, 08:00 ET

Immune Pharmaceuticals Announces New Data with Topical Cyclosporine Nano-Capsules in Dermatology

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP), "Immune", a clinical-stage biopharmaceutical company, announced today that following the review of...

Dec 28, 2015, 08:00 ET

Immune Pharmaceuticals Announces Exclusive License to a Novel Bispecific Antibody Technology

 Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune") a clinical-stage company developing novel therapies for the treatment of...

Dec 14, 2015, 07:30 ET

Immune Pharmaceuticals Announces New Data with Bi-Specific Antibody

 Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company") a clinical-stage company developing novel therapies for the treatment of...

Dec 09, 2015, 08:53 ET

Immune Pharmaceuticals CEO Updates Shareholders On Company Progress

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") a clinical-stage company developing novel therapies for the treatment...

Dec 07, 2015, 07:30 ET

G. John Mohr Joins Immune Pharmaceuticals as Senior Vice President of Business Development

 Immune Pharmaceuticals Inc. (NASDAQ:IMNP) ("Immune" or the "Company") a clinical-stage company developing novel therapies for the treatment of...

Nov 19, 2015, 07:30 ET

Immune Pharmaceuticals Expands Leadership Team

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") today announced two new additions to its leadership team: the appointment of...

Nov 17, 2015, 07:30 ET

Immune Pharmaceuticals Announces Enrollment of the First Patient into the Phase 2 Clinical Trial with Bertilimumab in Ulcerative Colitis

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announced today that the first patient has been enrolled into the Phase...

Nov 12, 2015, 07:30 ET

Immune Pharmaceuticals Announces Third Quarter 2015 Corporate Update, Financial Results and Conference Call Details

Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announces corporate update and three months and nine months ended September...

Nov 09, 2015, 07:30 ET

Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announced today that the U.S. Food and Drug Administration (FDA)...

Nov 05, 2015, 07:30 ET

Immune Pharmaceuticals to Announce Third Quarter 2015 Financial Results and Provide Corporate Update on November 12, 2015

 Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: IMNP) announced today it will release third quarter 2015 financial results and provide an...

Oct 15, 2015, 09:39 ET

Immune Pharmaceuticals to Present at Dawson James Growth Stock Conference

 Immune Pharmaceuticals Inc. (NASDAQ: IMNP) today announced, that Dr. Daniel Teper, CEO will present at the Dawson James Securities Growth...

Oct 07, 2015, 07:00 ET

Immune Pharmaceuticals Submits Investigational New Drug Application (IND) in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announced today that it has submitted an Investigational New Drug...

Oct 01, 2015, 19:00 ET

Immune Pharmaceuticals Receives Second Tranche of $3 Million from Discover Growth Fund

 Immune Pharmaceuticals, Inc. (IMNP) ("Immune or the "Company") announced today that Immune has received an additional $3 million in gross...

Sep 15, 2015, 17:00 ET

Immune Pharmaceuticals Announces Initiation of Stock Purchase Plan with up to $250,000 in Purchases by its CEO

 Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) ("Immune or the "Company") announced today that its Chief Executive Officer, Dr. Daniel Teper, has...

Sep 08, 2015, 08:00 ET

Dr. Boris Shor joins Immune Pharmaceuticals from Pfizer to lead new R&D lab at Alexandria Center for Life Science

 Immune Pharmaceuticals ("Immune" or "the company") (NASDAQ: IMNP) today announced that Boris Shor, Ph.D. has joined the company as...

Sep 03, 2015, 08:00 ET

Immune Pharmaceuticals Holds First R&D Day On September 8, 2015

Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) ("Immune" or the "Company") announced today that its first R&D day will take place...